Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships [Yahoo! Finance]
Bluejay Diagnostics, Inc. (BJDX)
Company Research
Source: Yahoo! Finance
Patient enrollment in SYMON-II clinical trial now approximately 50% completed. Recent private placement transaction completed in October 2025; Company continues to explore further financing opportunities. ACTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient testing solutions for critical care, announced financial results for the quarter ended September 30, 2025, and highlighted continued progress across its clinical, operational, and financial initiatives. Third Quarter 2025 and Recent Corporate Highlights SYMON-II Pivotal Clinical Study Continues: Bluejay continues patient enrollment in the SYMON-II pivotal clinical trial, designed to validate findings from its SYMON-I pilot study. The trial aims to assess the predictive performance of IL-6 levels in ICU patients for 28-day all-cause mortality. The Company's goal is to use the Symphony IL-6 test to complete
Show less
Read more
Impact Snapshot
Event Time:
BJDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BJDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BJDX alerts
High impacting Bluejay Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
BJDX
News
- Bluejay Diagnostics (NASDAQ:BJDX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Bluejay Diagnostics (NASDAQ:BJDX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic PartnershipsGlobeNewswire
- Bluejay Diagnostics (NASDAQ:BJDX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Bluejay Diagnostics (NASDAQ:BJDX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BJDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
BJDX
Sec Filings
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- 11/10/25 - Form 8-K
- BJDX's page on the SEC website